Want to see SRTA full AI Analyst Report?
SRTA Stock Chart & Stats
$4.57
--
Market closed
$4.57
--
Day’s Range― - ―
52-Week Range$3.68 - $6.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.23M
Market Cap
$452.53M
Enterprise Value$322.32
Total Cash (Recent Filing)$58.79M
Total Debt (Recent Filing)$4.47M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding86,526,570
10 Day Avg. Volume857,480
30 Day Avg. Volume1,233,622
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.75Price Target Upside113.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$272.93M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a substantial equity base give the company durable financial flexibility to fund organic growth, absorb operational volatility, and pursue M&A. Improved ROE indicates capital is being deployed more effectively, reducing downside risk over the medium term.
Rapid Clinical Build-outAccelerating Clinical revenue and strong sequential transplant growth signal successful cross-sell and product-market fit. A larger Clinical mix supports higher, more stable gross margins structurally and diversifies revenue beyond logistics cyclicalities.
Balance Sheet Cash & GuidanceMeaningful liquidity plus an undrawn ABL and reiterated guidance provide runway to execute expansion, absorb timing differences, and invest in fleet/hubs. This capacity underpins strategic optionality and reduces near-term financing dependence.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows increase reliance on balance-sheet liquidity or external financing, which can constrain long-term investment and magnify risk if revenue or margin trends reverse, undermining earnings quality despite recent net income.
Core Operating WeaknessProfitability driven by non-operating items or one-offs raises quality-of-earnings concerns. If core operations do not produce positive operating profit, margins and returns may be vulnerable, limiting sustainable free cash generation and long-term value creation.
Demand & Mix VariabilityDependence on donor volumes and fluctuating customer mix generates structural margin and revenue volatility. Logistics margins are sensitive to trip length and customer type, making forecasting and consistent margin expansion more difficult over a multi-quarter horizon.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical, Inc.’s price range in the past 12 months?
Strata Critical Medical, Inc. lowest stock price was $3.67 and its highest was $6.50 in the past 12 months.
What is Strata Critical Medical, Inc.’s market cap?
Strata Critical Medical, Inc.’s market cap is $452.53M.
When is Strata Critical Medical, Inc.’s upcoming earnings report date?
Strata Critical Medical, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 24 days.
How were Strata Critical Medical, Inc.’s earnings last quarter?
Strata Critical Medical, Inc. released its earnings results on May 06, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.068.
Is Strata Critical Medical, Inc. overvalued?
According to Wall Street analysts Strata Critical Medical, Inc.’s price is currently Undervalued.
Does Strata Critical Medical, Inc. pay dividends?
Strata Critical Medical, Inc. does not currently pay dividends.
What is Strata Critical Medical, Inc.’s EPS estimate?
Strata Critical Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Strata Critical Medical, Inc. have?
Strata Critical Medical, Inc. has 86,526,570 shares outstanding.
What happened to Strata Critical Medical, Inc.’s price movement after its last earnings report?
Strata Critical Medical, Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went up 10.581%.
Which hedge fund is a major shareholder of Strata Critical Medical, Inc.?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (113.35% Upside)
$9.75 (113.35% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $420.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.8%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.70%
12-Months-Change
Fundamentals
Return on Equity
18.97%
Trailing 12-Months
Asset Growth
30.76%
Trailing 12-Months
Company Description
Strata Critical Medical, Inc.
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
SRTA Stock 12 Month Forecast
Average Price Target
$9.75
▲(113.35% Upside)
Technical Analysis
Ownership Overview
14.91% Insiders
12.45% Mutual Funds
<0.01% Other Institutional Investors
62.25% Public Companies and
Individual Investors